Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: U.S. Court of Appeals confirms val idity of patent for UCB's Vimpat®

U.S. Court of Appeals confirms validity of patent for UCBs Vimpat®Court of Appeals for the Federal Circuit affirms Delaware District Court’s decisionBrussels Belgium, May 23rd, 2018 – 18.00 CEST – UCB announces that in a decision released today, the Court of Appeals for the Federal Circuit CAFC has affirmed the Delaware District Court and confirmed the validity of U.S. patent RE38,551... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Epilepsy as Global Health Priority

UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health prioritySignificant gaps in epilepsy management, awareness, and effective treatment access continue around the worldGroups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sustained commitment towards the... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Cimzia Non-Radiographic Axial Spondyloarthritis Study

CIMZIA® certolizumab pegol is The First Therapy to Demonstrate Positive Results in a 52week, Placebo Controlled NonRadiographic Axial Spondyloarthritis StudyPositive top line results from Phase 3 CAXSPAND study underscore the potential of CIMZIA for nonradiographic axial spondyloarthritis nraxSpA, and provide concrete evidence for the high burden of the disease and limitations of current... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room: Briviact FDA Pediatric

UCB announces BRIVIACT® brivaracetam now approved by FDA to treat partialonset focal seizures in pediatric epilepsy patientsBRIVIACT® brivaracetam CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partialonset seizures.Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose... See more
UCB [BE0003739530/UCB]   

UCB : UCB Media Room

UCB to present latest epilepsy scientific data and research perspectives at EILAT ConferenceBrussels Belgium, 11 May, 07:00 CET: UCB is set to present the latest preclinical and clinical data on its inmarket and developmental epilepsy portfolio and to describe new discovery avenues for drug resistance and disease modification during numerous presentations at the 14th EILAT Conference on New... See more